Finally, as many investors are aware, the Company has been the subject of various derogatory articles published by bloggers and penny stock newsletters. We take these statements and allegations very seriously and are working with our attorneys to evaluate all of our legal options. We will defend our Company and the hard work that so many people have put in to build our business. We thank you, our loyal shareholders and valued customers, for your continued support.
Sentiment: Strong Buy
As you can tell, not many people follow CIEN. It's a volatile stock. The reason it's going up now is the press fromm AT&T. That means bad press from AT&T can drag it down.
Realistically CIEN's revenue is not completely dependant on AT&T. I'm in manufacturing and our goal is a 10% margin of profit. With the economy, we're taking a 7% margin these days. So to answer your question, I'd figure on an 8% margin of profit to determine the bottom line profit to CIEN. Remember, you want to look at profit numbers, not revenue numbers. This recession has played havoc with margins with some companies making small margins just to keep the business.
After this nice run, i cashed out and will enter again after this fiscal cliff mess is resolved. AMCC is solid, but the run is being hampered by our wonderful representatives in Washington.
Sentiment: Strong Sell
If you have Scottrade, this press release was just released:
Antares Pharma has the Highest Revenue Per Employee in the Health Care Supplies Industry (AIS, VIVO, CERS)
3 minutes ago - Financial News Network Online - News Corner via Comtex
Below are the three companies in the Health Care Supplies industry with the highest Revenue Per Employee (RPE). Analysts use RPE as a measure to compare the productivity of companies in the same industry.Antares Pharma (AMEX:AIS) is highest with an RPE of $682,000. Antares Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. The Company distributes its needle-free injector systems in various countries. Antares also conducts research and development with transdermal gel products and has several products in clinical evaluation with partners. Antares Pharma has overhead space with shares priced $2.83, or 24.5% below the average consensus analyst price target of $3.75. The stock should find initial support at its 50-day moving average (MA) of $2.43 and further support at its 200-day MA of $2.29.
Meridian Bioscience (NASDAQ:VIVO) is next with an RPE of $573,000. Finishing up the top three is Cerus (NASDAQ:CERS), with an RPE of $418,000. ---------------------------------------------------------------------------------------------
Financial News Network Online (FNNO) is a leading provider of digital financial news content for distribution on the web. You can count on FNNO to bring you the latest market news, earnings reports, analyst comments, economic data reports and more. Visit http://www.fnno.com today.
I was watching the trades on Scottrade and already closed out the window. However, if you go to this link, you can set the time to the last one or five minutes and you will see the trade. GLTA
I've been quietly accumulating this stock and it keeps ticking up slowly. I like that. Nice even gains every week. Another 45,000 shares were bought at Ask right after the one above. This stock might break out soon.
It will depend on how quickly GTHP can sell units outside the US. If we can build momentum and sales start coming in, a whole new slew of investors will enter GTHP. Once the new FDA date is set, then the run-up will begin. Patience.
The key is not to panic. When I saw my net value of my account this morning, I wanted to scream. But you have to get past the initial panic and think long term. I was hoping for a large profit today last week. Now I'm looking at a large profit in six months. Patience.
I picked up 25,000 shares at .48505. I'm in this for the long haul. GTHP is oversold now with shorts covering this afternoon, it should go to .84 and close around .81 today. Maybe more. GTHP should be back in .90's withing 60 days and then begin the slow ascent again to 1.40.
$1.49 on Friday. Low of .43 this morning. Based on other stocks that have hit the FDA wall, I'm thinking 60 days to be back in the .90 range.
Sorry. I hope you didn't sell yet. GTHP should rebound later in the day. I still believe there will be another spike in about six month similar to what we saw this last time. Best of luck to you.